The Medical Letter on Drugs and Therapeutics
Dupilumab (Dupixent) for Asthma
The full article is available to subscribers Subscriber Login   

The FDA has approved the subcutaneously injected monoclonal antibody dupilumab (Dupixent – Sanofi/Regeneron) for add-on maintenance treatment of patients ≥12 years old with moderate to severe asthma with an eosinophilic phenotype or with oral corticosteroid-dependent asthma. Dupilumab was approved earlier to treat adults with moderate to severe atopic dermatitis inadequately controlled with topical therapies.1

MECHANISM OF ACTION — Dupilumab, a fully human IgG4 monoclonal antibody, binds to the interleukin (IL)-4 receptor alpha subunit shared by IL-4 and IL-13 receptors, inhibiting the signaling of these cytokines, which are thought to be the drivers of inflammation in atopic dermatitis, asthma, and possibly other allergic diseases.2

MONOCLONAL ANTIBODIES FOR ASTHMA — Asthma patients who do not respond ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Dupilumab (Dupixent) for Asthma
Article code: 1563c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian